Rôle de la MGMT et implications cliniques dans les tumeurs cérébrales

Translated title of the contribution: Role of MGMT and clinical applications in brain tumours

Christophe Paus*, Anastasia Murat, Roger Stupp, Luca Regli, Monika Hegi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Glioblastoma multiforme is the most common and most malignant primary brain tumour with a dismal prognosis. The advent of new chemotherapies with alkylating agents crossing the blood-brain barrier, like temozolomide, have permitted to notably ameliorate the survival of a subgroup of patients. Improved outcome was associated with epigenetic silencing of the MGMT (06-methylguanin methyltransferase) gene by promotor methylation, therby blocking its repair capability, thus rendering the alkylating agents more effective. This particularity can be tested by methylation specific PCR on resected tumour tissue, best on fresh frozen biopsies, and allows identification of patients more susceptible to respond favourably to the treatment.

Translated title of the contributionRole of MGMT and clinical applications in brain tumours
Original languageFrench
Pages (from-to)769-773
Number of pages5
JournalBulletin du cancer
Issue number9
StatePublished - Sep 2007


  • Glioblastoma
  • Methylation
  • Methylguanine methyltransferase

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Role of MGMT and clinical applications in brain tumours'. Together they form a unique fingerprint.

Cite this